Thiazide Diuretics
High-yield Verified · Oct 2026Block the Na-Cl cotransporter (NCC) of the distal convoluted tubule — the nephron’s last diluting segment, sitting just past the macula densa — so a little extra sodium reaches the collecting duct while calcium is pulled back into the blood.
Nursing view → administration, monitoring and patient teaching
Compare: Antihypertensives compared — mechanism and drug choice →
Drugs
Mechanism
Thiazide and thiazide-like diuretics act at the distal convoluted tubule, inhibiting the Na-Cl cotransporter (NCC). Because this segment reabsorbs only ~3–5% of filtered sodium, the diuresis is mild-to-moderate; the durable antihypertensive effect comes from an early fall in plasma volume followed by a chronic reduction in peripheral vascular resistance. Efficacy is lost at low GFR (except thiazide-like agents such as metolazone, chlorthalidone, and indapamide), and — unlike loops — they reduce urinary calcium, retaining calcium.
The target: NCC in the distal convoluted tubule
The distal convoluted tubule (DCT) begins at the macula densa and ends at the collecting duct, and reclaims only a few percent of filtered sodium — 3–5% by one estimate, 5–10% by another — mainly through the NCC, an electroneutral Na⁺–Cl⁻ symporter powered by the low intracellular sodium that the basolateral Na⁺/K⁺-ATPase maintains. Thiazides bind competitively to the chloride-binding site of NCC, its lone target in the DCT. Aldosterone, insulin, vasopressin and angiotensin II can all activate NCC. (Where the DCT sits among the other segments is shown on the loop-diuretic page.)
Because the DCT has no aquaporins it is the terminal diluting segment, which is why blocking it impairs urine dilution. Because it lies after the macula densa, thiazides do not trigger tubuloglomerular feedback; renin rises only through volume depletion, not through the low-salt signal that loops send to the macula densa.
Genetics confirms the target. Loss-of-function NCC mutations cause Gitelman syndrome — hypokalemic metabolic alkalosis, hypomagnesemia, hypocalciuria and lower blood pressure, mirroring thiazide effects — while gain-of-function NCC mutations cause Gordon syndrome (salt retention), which responds to thiazides.
From diuretic to antihypertensive
Early on, blood pressure falls because natriuresis lowers blood volume and cardiac output; a direct vasodilatory action has also been proposed. With chronic use plasma volume returns toward normal but peripheral vascular resistance stays lower, and the exact antihypertensive mechanism is not known. Theories include direct endothelial or vascular smooth-muscle vasodilation, probably by altering calcium regulation.
Thiazides do not lower normal blood pressure. Indapamide, for example, lowers peripheral resistance with little or no effect on cardiac output, rate or rhythm.
Calcium, magnesium and water
Calcium is retained by two routes. Proximally, volume depletion increases sodium reabsorption in the proximal tubule, which drags calcium along the paracellular pathway; distally, NCC blockade may enhance calcium reabsorption by modulating the TRPV5 channel. Urinary calcium can fall by up to 50%. On prolonged therapy a few patients develop parathyroid changes with hypercalcemia and hypophosphatemia, so thiazides are stopped before parathyroid-function testing. By contrast, loop diuretics cause calciuresis.
Magnesium is lost: NCC inhibition indirectly downregulates the TRPM6 magnesium channel.
Hyponatremia is commoner with thiazides than with loops even though loops block far more sodium reabsorption. Thiazides reduce free-water clearance (the DCT is where urine is diluted) without disturbing the medullary concentrating mechanism, and higher water intake and vasopressin secretion add to the dilution. It usually appears in the first 2–3 weeks.
The same physiology gives the nephrogenic diabetes insipidus paradox: by increasing distal sodium loss and causing mild volume depletion, a thiazide prompts compensatory proximal reabsorption of sodium and water, impairing the kidney’s maximum diluting capacity and reducing urine output.
Potassium, glucose, urate and lipids
Potassium is lost because more sodium reaches the aldosterone-sensitive collecting duct, which exchanges it for potassium and hydrogen ions (hypokalemic metabolic alkalosis). Reduced distal calcium delivery also stimulates ENaC and adds to potassium secretion. (The collecting-duct exchange is explained on the loop-diuretic page.)
Glucose rises through hypokalemia: low potassium hyperpolarizes pancreatic β-cells, potassium channels stay open, voltage-gated calcium channels fail to open, and too little calcium enters to trigger insulin exocytosis. Reduced insulin sensitivity adds to this.
Urate rises because thiazides are organic anions secreted in the proximal tubule in exchange for urate through organic anion transporters (OAT1 basolaterally, OAT4 on the lumen), so more urate is reabsorbed. Probenecid works by the opposite competition. Lipids: LDL cholesterol rises about 10%, total cholesterol about 4% and triglycerides almost 15%, with HDL unaffected; the effect is dose-dependent and less with low doses.
Comparing the drugs
The four drugs
| Drug | Chemical class | Duration | Low-GFR efficacy | Distinctive point |
|---|---|---|---|---|
| Hydrochlorothiazide | Thiazide-type (benzothiadiazine) | Half-life 6–15 h; action up to 24 h | Effect declines as GFR falls | Non-melanoma skin cancer signal (mainly squamous cell, large cumulative doses) |
| Chlorthalidone | Thiazide-like | Half-life 40–60 h; diuresis up to 72 h | Maintains efficacy at GFR < 30 | Sequestered by red-cell carbonic anhydrase, a slow-release reservoir |
| Metolazone | Thiazide-like (quinazoline) | Diuresis begins within 1 h and lasts 24 h or more | Can produce diuresis at GFR < 20 mL/min | Marked diuresis with furosemide in refractory edema; formulations not interchangeable |
| Indapamide | Thiazide-like (indoline) | Whole-blood half-life about 14 h | Antihypertensive in renal impairment; maintains efficacy at GFR < 30 | Extensively metabolized (about 7% excreted unchanged) |
Thiazide-like agents lack the benzothiadiazine backbone but act on the same transporter.
Pharmacokinetics at a glance
| Drug | Absorption | Protein binding | Elimination |
|---|---|---|---|
| Hydrochlorothiazide | 65–75% absorbed; less in heart failure | 40–68% | Renal; over 95% of the absorbed dose excreted unchanged |
| Chlorthalidone | About 65% bioavailable | About 75% | Mainly unchanged in urine |
| Metolazone | Peak blood level about 8 h after a dose | About 95% | Mostly unchanged in urine; not removed by dialysis |
| Indapamide | Peak within 2 h | 71–79% | At least 70% renal and 23% gastrointestinal, mostly as metabolites |
Pharmacokinetics
- Absorption and bioavailability
- Thiazides are readily absorbed; oral bioavailability ranges from 50% to 95% (about 70% for hydrochlorothiazide and 65% for chlorthalidone). Food reduces hydrochlorothiazide bioavailability by about 10%, and heart failure reduces its absorption.
- Red-cell sequestration — chlorthalidone, indapamide
- Chlorthalidone binds red-cell carbonic anhydrase and reaches 7–10 times its plasma concentration in red cells, which act as a reservoir releasing it slowly — the basis of its long half-life and once-daily use. Indapamide is also preferentially taken up by red cells (whole blood : plasma about 6 : 1 at peak).
- Metabolism — indapamide, metolazone
- Most thiazides are not metabolized and are excreted unchanged. Indapamide is the exception — extensively metabolized, with only about 7% recovered unchanged in urine; only a small fraction of metolazone is metabolized.
- Renal elimination and low GFR
- Hydrochlorothiazide and chlorthalidone are eliminated mainly unchanged by the kidney, and hydrochlorothiazide’s half-life lengthens in renal disease. Thiazides lose diuretic and antihypertensive effect as GFR falls, but chlorthalidone, metolazone and indapamide maintain it at GFR below 30 mL/min/1.73 m².
- Onset and duration
- Hydrochlorothiazide acts within 2 hours, peaks at about 4 hours and lasts up to 24 hours; chlorthalidone’s diuresis starts at about 2.6 hours and continues up to 72 hours; metolazone’s begins within 1 hour.
- Placenta and milk — hydrochlorothiazide
- Hydrochlorothiazide crosses the placenta, does not penetrate the blood–brain barrier, and is excreted in breast milk.
Uses & drug choice
- Hypertension — first-line (chlorthalidone/HCTZ)
- Edema of mild heart failure and renal or hepatic disease (early CKD stages)
- Prevention of calcium kidney stones (reduce urinary calcium)
- Metolazone + a loop diuretic for resistant/refractory edema
Adverse effects
- Increased urination, dizziness, orthostatic hypotension and dehydration
- Natriuresis lowers blood volume and cardiac output.
- Hypokalemia and metabolic alkalosis
- Extra sodium reaching the collecting duct is exchanged, under aldosterone, for potassium and hydrogen ions; volume depletion activates the RAAS, and reduced distal calcium delivery stimulates ENaC.
- Hyponatremia
- The DCT is the terminal diluting segment: blocking it reduces free-water clearance while concentrating ability stays intact, and vasopressin and water intake add to the dilution.
- Hyperglycemia
- Hypokalemia hyperpolarizes pancreatic β-cells, keeping calcium channels closed and reducing insulin secretion; insulin sensitivity also falls.
- Hyperuricemia and gout
- Thiazides are secreted by proximal-tubule organic anion transporters in exchange for urate, increasing urate reabsorption.
- Hypercalcemia
- Calcium reabsorption rises proximally (paracellular, driven by volume depletion) and distally (NCC blockade may enhance it through TRPV5), so urinary calcium falls and serum calcium can rise.
- Hyperlipidemia
- The mechanism is unclear; LDL cholesterol and triglycerides rise in a dose-dependent way, with HDL unaffected.
- Hypomagnesemia
- NCC inhibition indirectly downregulates the TRPM6 magnesium channel in the DCT.
- Sulfonamide reactions, including acute myopia and angle-closure glaucoma
- Thiazides are sulfonamide derivatives; hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction leading to acute transient myopia and acute angle-closure glaucoma.
- Lithium toxicity and digoxin toxicity
- Thiazides increase proximal-tubule lithium reabsorption. Digoxin competes with potassium for its binding site on Na⁺/K⁺-ATPase, so diuretic-induced hypokalemia leaves digoxin’s action unopposed.
Toxicity & antidote
Overdose produces hypokalemia, hyponatremia and dehydration from excessive diuresis, and can cause acute kidney injury; with concurrent digoxin, the hypokalemia raises the risk of arrhythmias. Treatment corrects dehydration, hypotension and electrolytes; metolazone has no antidote. Metolazone is not removed by dialysis because of its high protein binding, and how much hydrochlorothiazide hemodialysis removes is uncertain.
Interactions
Contraindications
- Anuria — No urine output means no diuretic effect and needless risk — a labeled contraindication.
- Sulfonamide hypersensitivity — Thiazides are sulfonamide derivatives; the label contraindicates use with hypersensitivity to sulfonamide-derived drugs (true cross-reactivity is considered low).
- Advanced renal impairment (GFR <~30 mL/min) use caution — Thiazides lose efficacy at low GFR (except thiazide-like agents such as metolazone) and can precipitate azotemia — switch to a loop diuretic.
- Gout, diabetes, hypokalemia, hypercalcemia, or concurrent lithium/digoxin use caution — Thiazides raise uric acid and glucose, lower potassium, retain calcium, and reduce lithium clearance — use caution and monitor.
High-yield
- D — distal convoluted tubule: NCC is blocked
- C — calcium reabsorption rises (proximal paracellular; possibly distal via TRPV5); urinary calcium falls by up to 50%
- C — consequences: helps calcium-stone formers; avoid for symptomatic hypercalcemia (loops cause calciuresis instead)
- C — chlorthalidone
- M — metolazone
- I — indapamide: these thiazide-like agents maintain efficacy at GFR below 30 mL/min/1.73 m², unlike hydrochlorothiazide
Practice questions
Q1A 79-year-old woman started hydrochlorothiazide for hypertension 2 weeks ago. She is brought in with new confusion; serum sodium is 121 mEq/L. Her daughter notes she drinks a lot of water.
Why does this complication occur more often with thiazides than with loop diuretics?
- A.Thiazides block more sodium reabsorption than loop diuretics
- B.Thiazides directly stimulate vasopressin V2 receptors
- C.Thiazides impair urine dilution in the DCT while leaving the medullary concentrating mechanism intact
- D.Thiazides inhibit the Na⁺/K⁺-ATPase in the collecting duct
- E.Thiazides increase sodium loss through the gut
Show answer
C. Thiazides impair urine dilution in the DCT while leaving the medullary concentrating mechanism intact — Loops actually block far more sodium reabsorption, yet hyponatremia is commoner with thiazides: they reduce free-water clearance by blocking the terminal diluting segment while the countercurrent concentrating mechanism stays intact. Higher water intake and vasopressin secretion add to the dilution, and the problem usually appears in the first 2–3 weeks of therapy.
Q2A 45-year-old man has had three calcium oxalate stones. A 24-hour urine collection shows hypercalciuria with normal serum calcium. He is started on chlorthalidone and potassium citrate.
How does chlorthalidone lower his urinary calcium?
- A.By suppressing parathyroid hormone secretion
- B.By increasing tubular calcium reabsorption, proximally with volume depletion and possibly distally after NCC blockade
- C.By blocking NKCC2 in the thick ascending limb
- D.By increasing urinary citrate excretion
- E.By inhibiting intestinal calcium absorption
Show answer
B. By increasing tubular calcium reabsorption, proximally with volume depletion and possibly distally after NCC blockade — Thiazides increase calcium reabsorption: volume depletion boosts proximal sodium reabsorption, which carries calcium paracellularly, and NCC blockade may enhance distal reabsorption through TRPV5. Urinary calcium can fall by up to 50%, an effect StatPearls attributes to increased renal tubular calcium reabsorption. Potassium citrate is added because thiazides also lower serum potassium and urinary citrate. NKCC2 is the loop-diuretic target, and loops cause calciuresis.
Q3A 22-year-old woman has muscle cramps. Labs show potassium 2.9 mEq/L, bicarbonate 31 mEq/L, magnesium 1.3 mg/dL and low urinary calcium; her blood pressure is low-normal. She takes no medications, and genetic testing finds a loss-of-function mutation in a distal tubule transporter.
Which drug produces the same pattern?
- A.Hydrochlorothiazide
- B.Furosemide
- C.Spironolactone
- D.Acetazolamide
- E.Mannitol
Show answer
A. Hydrochlorothiazide — This is Gitelman syndrome — loss of function of NCC, the thiazide target — with hypokalemic metabolic alkalosis, hypomagnesemia, hypocalciuria and lower blood pressure. A thiazide reproduces it pharmacologically. Furosemide is excluded by the low urinary calcium, because loop diuretics cause calciuresis. Spironolactone produces the opposite pattern — potassium-sparing diuretics cause hyperkalemia and a hyperchloremic metabolic acidosis — and acetazolamide, a carbonic anhydrase inhibitor, also causes a hyperchloremic metabolic acidosis rather than an alkalosis. Mannitol is an osmotic diuretic that does not interfere with electrolyte reabsorptive mechanisms, so it mimics no transporter defect.
Q4A 60-year-old man with hypertension develops new hyperglycemia and a serum potassium of 3.1 mEq/L six months after starting chlorthalidone.
Which mechanism links the two findings?
- A.Chlorthalidone directly destroys pancreatic β-cells
- B.Hypokalemia increases hepatic glucose uptake
- C.Chlorthalidone stimulates glucagon release through NCC on α-cells
- D.Hypokalemia blocks GLUT4 in skeletal muscle
- E.Low potassium hyperpolarizes β-cells, keeping voltage-gated calcium channels closed and reducing insulin release
Show answer
E. Low potassium hyperpolarizes β-cells, keeping voltage-gated calcium channels closed and reducing insulin release — Thiazide-induced hypokalemia hyperpolarizes pancreatic β-cells: potassium channels stay open, voltage-gated calcium channels fail to open, and too little calcium enters to trigger insulin exocytosis. Reduced insulin sensitivity also contributes.
Q5A 70-year-old man with heart failure remains edematous despite high-dose furosemide. Metolazone is added, and his urine output rises sharply over the next day.
What best explains the added diuresis?
- A.Metolazone antagonizes aldosterone receptors
- B.Metolazone increases furosemide absorption from the gut
- C.Metolazone inhibits carbonic anhydrase
- D.Metolazone blocks the compensatory distal sodium reabsorption that blunts the loop diuretic
- E.Metolazone blocks NKCC2 at a second site
Show answer
D. Metolazone blocks the compensatory distal sodium reabsorption that blunts the loop diuretic — Adding a thiazide-like drug to a loop diuretic interferes with compensatory distal tubular sodium reabsorption, increasing natriuresis, and metolazone can work even when GFR is below 20 mL/min. Metolazone does not inhibit carbonic anhydrase. Watch for hypokalemia, hyponatremia and worsening renal function.
Sources
- Thiazide Diuretics — DCT/NCC mechanism, calcium retention, metabolic effects & low-GFR limit — StatPearls (NCBI)
- Metolazone — retained low-GFR efficacy & loop-diuretic synergy — StatPearls (NCBI)
- Hydrochlorothiazide — early (morning) dosing to limit nocturia, sun protection, electrolytes — StatPearls (NCBI)
- Open RN Nursing Pharmacology — Ch. 6 Cardiovascular & Renal (thiazide grid: potassium-rich diet) — Open RN (NCBI Bookshelf)
- Hydrochlorothiazide capsules — prescribing information (contraindications, acute myopia/angle-closure glaucoma, lithium, electrolytes) — DailyMed (NLM)
- Metolazone tablets — prescribing information (furosemide combination) — DailyMed (NLM)
- Drugs@FDA — MICROZIDE (NDA 020504) marketing status — U.S. FDA
- Therapeutic Uses of Diuretic Agents — DCT sodium, CKD, calcium, hyponatremia — StatPearls (NCBI)
- Chlorthalidone — potency and duration vs HCTZ — StatPearls (NCBI)
- Antihypertensive Medications — thiazide metabolic effects, hyponatremia in older women — StatPearls (NCBI)
- Hyperuricemia — normal serum uric acid — StatPearls (NCBI)
- Resistant Hypercalcemia — normal serum calcium — StatPearls (NCBI)
- Hyponatremia — serum sodium — StatPearls (NCBI)
- Peroxidase-Coupled Glucose Method — normal fasting glucose 70–99 mg/dL — StatPearls (NCBI)
- StatPearls: Hypocalcemia (normal total calcium 8.5–10.5 mg/dL) — StatPearls (NCBI)
- Thalitone (chlorthalidone) tablets — thiazide-like diuretic for hypertension and edema (FDA label) — FDA / DailyMed
- Hypercalciuria — thiazides cut urinary calcium; potassium citrate — StatPearls (NCBI)
- Indapamide tablets — clinical pharmacology (FDA label) — FDA / DailyMed
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.